COYA

Coya Therapeutics, Inc. Announces Preclinical Data Supporting the Role of Expanded Regulatory T Cells (Tregs) as Potential Disease-Modifying Treatment in an Animal Model of Alzheimer’s Disease (AD)

Retrieved on: 
Thursday, January 26, 2023
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Houston Methodist Hospital, Brain, Animal, Microglia, Patient, C1QA, Cell, Therapy, Astrocyte, Dirichlet function, Pathology, Transcriptome, IL1A, CD14, IL6, Rhodopsin-like receptors, COYA, MD, Pharmaceutical industry, Regulatory T cell, Dentate gyrus, Histamine receptor

The preclinical study was conducted by Ali Faridar, M.D., of Houston Methodist Hospital (Houston, Texas), under the leadership of Stanley Appel, M.D., the chair of Coya’s Scientific Advisory Board.

Key Points: 
  • The preclinical study was conducted by Ali Faridar, M.D., of Houston Methodist Hospital (Houston, Texas), under the leadership of Stanley Appel, M.D., the chair of Coya’s Scientific Advisory Board.
  • “These data further support that enhancing Treg function is a potential strategy to ameliorate neuroinflammation, which may modify Alzheimer’s Disease-associated pathology in the brain.
  • Stanley Appel, MD., Professor, Houston Methodist Hospital and Chair of Coya’s Scientific Advisory Board, commented, “Dr.
  • Furthermore, Treg-treated mice showed significant reduction in total and plaque-associated microglia as well as reactive astrocytes in dentate gyrus and frontal cortex versus untreated mice.

Coya Therapeutics, Inc. Announces Closing of $15.25 Million Initial Public Offering

Retrieved on: 
Tuesday, January 3, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Therapy, Bangladesh Securities and Exchange Commission, McGuireWoods, Suite, Security (finance), Form, Prospectus, Newbridge, State Street, COYA, Sale, Enterprise file synchronization and sharing

Coya Therapeutics, Inc. (“Coya” or the “Company”) (Nasdaq: COYA), a clinical-stage biotechnology company developing proprietary therapies to enhance the function of regulatory T cells (“Tregs”), today announced the closing of its initial public offering of 3,050,000 shares of its common stock and accompanying warrants to purchase up to 1,525,000 shares of common stock.

Key Points: 
  • Coya Therapeutics, Inc. (“Coya” or the “Company”) (Nasdaq: COYA), a clinical-stage biotechnology company developing proprietary therapies to enhance the function of regulatory T cells (“Tregs”), today announced the closing of its initial public offering of 3,050,000 shares of its common stock and accompanying warrants to purchase up to 1,525,000 shares of common stock.
  • Each share of common stock and accompanying warrant were sold at a combined offering price of $5.00, for gross proceeds of approximately $15.25 million, before deducting underwriting discounts and offering expenses.
  • In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 290,000 shares of common stock and/or warrants to purchase 145,000 shares of common stock to cover over-allotments at the initial public offering price, less the underwriting discount.
  • A final prospectus relating to the offering was filed with the SEC and is be available on the SEC’s website at http://www.sec.gov .

Coya Therapeutics, Inc. Announces Pricing of $15.25 Million Initial Public Offering

Retrieved on: 
Thursday, December 29, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Therapy, Bangladesh Securities and Exchange Commission, Suite, Security (finance), Form, Prospectus, Newbridge, State Street, COYA, Sale, Enterprise file synchronization and sharing

Coya Therapeutics, Inc. (“Coya” or the “Company”) (Nasdaq: COYA), a clinical-stage biotechnology company developing proprietary therapies to enhance the function of regulatory T cells (“Tregs”), today announced the pricing of its initial public offering of 3,050,000 shares of its common stock and accompanying warrants to purchase up to 1,525,000 shares of common stock.

Key Points: 
  • Coya Therapeutics, Inc. (“Coya” or the “Company”) (Nasdaq: COYA), a clinical-stage biotechnology company developing proprietary therapies to enhance the function of regulatory T cells (“Tregs”), today announced the pricing of its initial public offering of 3,050,000 shares of its common stock and accompanying warrants to purchase up to 1,525,000 shares of common stock.
  • Each share of common stock and accompanying warrant is being sold at a combined offering price of $5.00, for gross proceeds of approximately $15.25 million, before deducting underwriting discounts and offering expenses.
  • Net proceeds, after underwriting discounts, commissions and estimated offering expenses, are expected to be approximately $13.2 million.
  • The offering is being made only by means of a prospectus forming part of the effective registration statement.

Coya Therapeutics, Inc. Announces Peer-Reviewed Publication of Phase 2a Clinical Trial Data for COYA 101 in Amyotrophic Lateral Sclerosis (ALS)

Retrieved on: 
Thursday, September 1, 2022
Amyotrophic lateral sclerosis, Inflammation, Neuroinflammation, Patient, COVID-19, HIV disease progression rates, Houston Methodist Hospital, Safety, Therapy, Protein, DB, Disease, ITT, Open-label trial, Phenotype, COYA, Particle-size distribution, OLR1, Disability, GLOBE, FTD, Exosome, Neuro, Coronavirus Scientific Advisory Board (Turkey), Biomarker, Oxidative stress, ALS, OLE, Medical device, Pharmaceutical industry, Person, Regulatory T cell, Regulatory T cell, Neuroimmunology, Scleroderma, Fibrosis

Coya has an exclusive worldwide license from Houston Methodist Hospital to develop, manufacture, and commercialize COYA 101.

Key Points: 
  • Coya has an exclusive worldwide license from Houston Methodist Hospital to develop, manufacture, and commercialize COYA 101.
  • Subjects enrolled in the Phase 2a trial were initially randomized into a double-blind portion to receive active Treg cells or matching placebo every four weeks over 24 weeks.
  • The DB portion of the trial was curtailed due to COVID-19-related restrictions, and the limited number of patients enrolled made statistical analysis not feasible.
  • The Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) is a validated rating instrument that gauges the progression of disability in patients with amyotrophic lateral sclerosis (ALS) on a 48-point scale.

Coya Therapeutics Secures $10 Million Financing to Advance Clinical and Pre-Clinical Pipeline of Regulatory T Cell Therapeutics

Retrieved on: 
Tuesday, June 7, 2022
FTD, Science, Degenerative disease, Exosome, LLC, Disease, Amyotrophic lateral sclerosis, Inflammation, IND, Therapy, Autoimmunity, GLOBE, Patient, ALS, Lists of diseases, Immune system, Coya, COYA, Protein, Pharmaceutical industry, Scleroderma, Regulatory T cell, Regulatory T cell, Fibrosis

The financing brings the total funding to date to over $20 million.

Key Points: 
  • The financing brings the total funding to date to over $20 million.
  • Coya is also preparing a novel biologic program for IND submission for ALS, FTD, and Alzheimers disease patients.
  • Our team at Coya is dedicated towards the successful development of our novel Treg modalities, each of which can meaningfully enhance Treg function, concluded Dr. Berman.
  • Headquartered in Houston, TX, Coya Therapeutics, Inc. (Coya) is a clinical-stage biotechnology company developing first-in-class and best-in-class approaches utilizing adoptive regulatory T cells (Tregs) to target systemic and neuroinflammation.

Coya Therapeutics Announces Annals of Neurology Publication Featuring Biomarker Data in ALS Patients Treated with Tregs Cell Therapy

Retrieved on: 
Wednesday, April 27, 2022
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, ALS, COYA, C-reactive protein, Annals of Neurology, Exosome, T cell, Coya, App, American Neurological Association, Houston Methodist Hospital, Frontotemporal dementia, Oxidative stress, OS, Patient, Biomarker, Amyotrophic lateral sclerosis, Lipid, Chair, Neurodegeneration, Degenerative disease, APP, HIV disease progression rates, CD14, Neuroinflammation, Therapy, Pharmaceutical industry, Neurology, Regulatory T cell

The published study data support the proposed mechanism of action and biological activity of expanded Tregs, and these findings were consistent in a subsequent Phase 2a study in ALS patients.

Key Points: 
  • The published study data support the proposed mechanism of action and biological activity of expanded Tregs, and these findings were consistent in a subsequent Phase 2a study in ALS patients.
  • Our laboratory has long documented that peripheral inflammatory constituents such as lipid peroxides and acute phase proteins are increased in ALS patients, with levels more markedly elevated in fast progressing patients.
  • Our new data demonstrates that Treg Cell therapy enhances suppression of proinflammatory biomarkers and, in turn, correlates with slowing of disease progression.
  • The first round of ex-vivo expanded Treg cell therapy suppressed levels of oxidized low-density lipoprotein (ox-LDL).

The Hottest 10 New Restaurants Coming to Qatar in 2022

Retrieved on: 
Wednesday, February 23, 2022
GLOBE, Budget, COYA, Sand, Azure Beach Club Paris Hilton, Qatar Airways, City, Population, Hotel Le Royal, The Pearl-Qatar, Family, FIFA, Culture, Disc jockey, Language, Heart, Babel, Octa, Tourism, Sport, Life, Michelin, EL, Press service, Quality engineering, Astoria, KAIA, Restaurant, Hotel, Qatar Tourism Authority

DOHA, Qatar, Feb. 23, 2022 (GLOBE NEWSWIRE) -- With the FIFA World Cup Qatar 2022TM bringing the world to its Middle Eastern peninsula this year, Qatar is welcoming a wave of new international restaurants.

Key Points: 
  • DOHA, Qatar, Feb. 23, 2022 (GLOBE NEWSWIRE) -- With the FIFA World Cup Qatar 2022TM bringing the world to its Middle Eastern peninsula this year, Qatar is welcoming a wave of new international restaurants.
  • So, for those on the hunt for the most sensational new culinary hotspots, Qatar Tourism has rounded up some of the most mouth-watering restaurants to look forward to in 2022.
  • Coming from restaurateur Kurt Zdesar, Chotto Matte will open at The St. Regis Marsa Arabia Island, The Pearl Qatar.
  • Travellers set to transit through Qatar should turn one holiday into two with the world's best value stopover packages, launched by Qatar Airways and Discover Qatar and supported by Qatar Tourism.

Coya Therapeutics Applauds U.S. House of Representatives for Passing ACT for ALS

Retrieved on: 
Friday, December 10, 2021
ACT, Coya, Patient, Representative, Cryopreservation, COYA, ALS, Disease, Food and Drug Administration Amendments Act of 2007, Senate, House, FDA, Food, Clinical trial, Frontotemporal dementia, Industry, HHS, Research, Company, Safety, Therapy, Exosome, Louisiana House of Representatives, Degenerative disease, Neurodegeneration, TM, GLOBE, Pharmaceutical industry

HOUSTON, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Coya Therapeutics, Inc. (Coya or the Company), a clinical-stage biotechnology company developing first-in-class approaches utilizing autologous regulatory T cells (Treg) and Treg-derived exosome therapeutics for neurodegenerative and autoimmune diseases, applauds the U.S. House of Representatives for its decision to pass H.R.

Key Points: 
  • HOUSTON, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Coya Therapeutics, Inc. (Coya or the Company), a clinical-stage biotechnology company developing first-in-class approaches utilizing autologous regulatory T cells (Treg) and Treg-derived exosome therapeutics for neurodegenerative and autoimmune diseases, applauds the U.S. House of Representatives for its decision to pass H.R.
  • 3537 , the Accelerating Access to Critical Therapies for ALS Act (ACT for ALS).
  • ACT for ALS is bipartisan legislation aimed at establishing grant programs to address neurodegenerative diseases, such as Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease).
  • We at Coya strongly urge the Senate to follow the Houses lead and move this forward to help those affected by ALS, commented Howard Berman, Ph.D., Chief Executive Officer of Coya Therapeutics.